Selectivity

Understanding Selectivity

Selectivity quantifies target preference:

                    High selectivity: 1000x
                    ┌─────────────────────┐
                    ↓                     ↓
Target A: EC50 = 1 nM            Target B: EC50 = 1000 nM
(intended)                       (off-target)

Calculating Selectivity Ratio

Selectivity = EC50 (or IC50) off-target / EC50 target

Drug	Target EC50	Off-target EC50	Selectivity
Highly selective	1 nM	10,000 nM	10,000x
Moderately selective	1 nM	100 nM	100x
Non-selective	1 nM	2 nM	2x

Selectivity vs Specificity

These terms are often confused:

Aspect	Selectivity	Specificity
Definition	Preference for one target over others	Ability to bind only the intended target
Measurement	Ratio of potencies	Binding to target vs non-target
Spectrum	Degrees (10x, 100x, 1000x)	Often binary (specific vs non-specific)
Clinical implication	Reduced side effects at therapeutic doses	Predictable, targeted action

Key insight: A selective drug interacts more strongly with its target but may still affect others at high concentrations. A specific drug exclusively affects its target.

Why Selectivity Matters

Therapeutic Window

Effect
    |    Target      Off-target
    |      /            /
    |     /            /
    |    /            /
    |___/______|_____/____
               ↑
         Therapeutic
           Window

Higher selectivity widens the therapeutic window - the dose range where you get benefit without side effects.

Side Effect Profile

Selectivity Level	Typical Side Effect Profile
1000x+	Minimal off-target effects
100-1000x	Some effects at high doses
10-100x	Significant off-target potential
Under 10x	Expected off-target effects

Selectivity in Peptide Research

Growth Hormone Secretagogues

Peptide	GHS-R	Other Targets	Selectivity
Ipamorelin	High	Minimal cortisol/prolactin	High
GHRP-6	High	Increases cortisol, prolactin	Moderate
GHRP-2	High	Some cortisol effect	Moderate

Ipamorelin’s selectivity makes it preferred for users wanting GH release without hormonal side effects.

GLP-1/GIP Agonists

Agonist	GLP-1R	GIPR	Design Intent
Semaglutide	High	None	GLP-1 selective
Tirzepatide	High	High	Intentional dual agonist
Native GLP-1	High	None	Naturally selective

Tirzepatide is intentionally non-selective between GLP-1R and GIPR - dual activation provides enhanced efficacy.

Achieving Selectivity in Drug Design

Structural Approaches

Strategy	Mechanism	Example
Subtype selectivity	Target receptor subtypes	Beta-1 vs Beta-2 selective
Tissue selectivity	Tissue-specific expression	SARM compounds
Kinetic selectivity	Different binding kinetics	Slow off-rate at target

Limitations

Even highly selective drugs may affect off-targets when:

• Used at high doses
• Accumulated in specific tissues
• Metabolized to non-selective compounds
• Receptor expression changes in disease states

Measuring Selectivity

Selectivity Panel

Standard drug development includes testing against panels of related targets:

Target Type	Purpose
Related receptors	Direct competition for binding
Receptor subtypes	Subtype preference
Off-target enzymes	Metabolic interactions
Ion channels	Safety (cardiac, neurological)

Frequently Asked Questions

Can a drug be too selective?

Rarely, but yes. Some conditions benefit from multi-target drugs. Depression often responds better to drugs affecting multiple neurotransmitter systems. Cancer therapies increasingly combine mechanisms. Tirzepatide’s dual GLP-1/GIP action outperforms highly selective GLP-1 agonists.

How is selectivity determined?

By measuring potency (EC50/IC50) at the target and at a panel of potential off-targets. The ratio of these values gives selectivity. Comprehensive panels may test 50-100+ potential off-targets.

Does selectivity guarantee no side effects?

No. Side effects can arise from on-target activity in unintended tissues (the target receptor exists elsewhere in the body), downstream pathway effects, or individual variation. Selectivity reduces but doesn’t eliminate side effect risk.